Sign In

Ashutosh Jogalekar

Drug design, technology assessment

Ashutosh Jogalekar is a highly experienced scientist with over ten years of experience in modeling, simulation, and early-stage drug discovery. He has particular expertise in structure-based design, HTS data analysis, and library design of small molecules. Ashutosh is currently working at Revolution Medicines, where he is designing leads for high-value cancer targets and adopting promising experimental and computational technologies. He has previously worked at Warp Drive Bio and Ensemble Therapeutics, where he worked on frontier drug targets and created and validated high-value chemical matter for unmet therapeutic needs.

Aside from his professional experience, Ashutosh is also an accomplished science writer and historian, having written for Scientific American and been an official journalist at the Lindau Meeting of Nobel Laureates. His interests include the history and philosophy of science and technology.

Highlights

The demise of Scientific American: Guest post by Ashutosh Jogalekar
Oct 1 · 3quarksdaily.com
On Nobel Prizes, diversity and tool-driven scientific revolutions
Jul 1 · aacrjournals.org
Abstract 4878: RMC-4550, an allosteric inhibitor of SHP2
Apr 2 · cen.acs.org
Rise of the smartish machines - C&EN - American Chemical Society
Rise of the smartish machines - C&EN - American Chemical Society

Related Questions

What are Ashutosh Jogalekar's main research interests at Revolution Medicines?
How has Ashutosh Jogalekar contributed to drug discovery in his career?
What projects has Ashutosh Jogalekar led at Revolution Medicines?
How does Ashutosh Jogalekar view the integration of AI in drug discovery?
What are Ashutosh Jogalekar's key achievements in computational chemistry?
A
Add to my network

Location

San Francisco Bay Area